Company: TXG
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001770787-25-000013
Chunk: 4

Company: 10x Genomics, Inc.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 8
Chunk 4
---
116)Realized loss on available-for-sale marketable securities reclassified into net loss3 1,718 — Foreign currency translation adjustment(273)(22)(241)Other comprehensive income (loss), net of tax(64)3,906 (4,357)Comprehensive loss$(182,691)$(251,193)$(170,357)

The accompanying notes are an integral part of these consolidated financial statements.

81

10x Genomics, Inc.

Consolidated Statements of Stockholders’ Equity

(In thousands, except share data)

Common StockAdditionalPaid-inCapitalAccumulatedDeficitAccumulatedOtherComprehensiveIncome (Loss)TotalStockholders’EquitySharesAmountBalance as of December 31, 2021112,514,977 $2 $1,680,865 $(863,321)$22 $817,568 Issuance of Class A common stock related to equity awards2,680,032 — 21,226 — — 21,226 Vesting of shares subject to repurchase, including early exercised options— — 96 — — 96 Stock-based compensation— — 137,210 — — 137,210 Net loss— — — (166,000)— (166,000)Other comprehensive loss— — — — (4,357)(4,357)Balance as of December 31, 2022115,195,009 2 1,839,397 (1,029,321)(4,335)805,743 Issuance of Class A common stock related to equity awards3,900,353 — 19,483 — — 19,483 Stock-based compensation— — 167,010 — — 167,010 Net loss— — — (255,099)— (255,099)Other comprehensive income— — — — 3,906 3,906 Balance as of December 31, 2023119,095,362 2 2,025,890 (1,284,420)(429)741,043 Issuance of Class A common stock related to equity awards3,196,475 — 10,914 — — 10,914 Stock-based compensation— — 140,868 — — 140